After a series of offers, Takeda (TYO:4502) said today that it reached an agreement with Shire (NSDQ:SHPG) to acquire the U.S.-based company in a deal valued at $62 billion. The merger was approved by both companies’ boards of directors, according to Takeda, and is slated to close in the first half of 2019. Takeda investors are wary […]
Shire
Shire accepts $64B takeover bid from Takeda
Shire (NSDQ:SHPG) said late yesterday it agreed to Takeda Pharmaceutical‘s (TYO:4502) reworked acquisition bid, now worth approximately $64.2 billion (GBP £46 billion). The takeover offer will now go to Shire’s shareholders for approval, having received backing from Dublin, Ireland-based Shire’s board of directors, according to a press release. In the deal, Takeda will offer approximately 0.839 […]
Report: Takeda raises $60B offer for Shire, nears prelim acquisition agreement
Takeda Pharmaceutical (TYO:4502) has sweetened its approximately $60 billion bid for Shire (NSDQ:SHPG) and is approaching a preliminary agreement for acquisition, according to a new report from Bloomberg. The deal could come to a head as early as today, according to the report, as both companies have been working on a tentative agreement and price for the […]
Update: Allergan, Takeda spar for Shire
Hours after Allergan (NYSE:AGN) said it was considering an acquisition of Shire (NSDQ:SHPG), the Dublin-based company announced that it does not intend to make such an offer. Reports also surfaced today that Shire rejected a $63 billion takeover offer from Takeda Pharmaceutical (TYO:4502). Reuters, which first broke the news of Allergan’s interest in Shire, citing a pair of unnamed sources, […]
Ex-Advanced BioHealing exec draws probation in VA fraud case
A former Advanced BioHealing executive who admitted to federal charges that he bribed U.S. Veterans Affairs Dept. doctors to use the company’s DermaGraft biologic wound dressing last week drew probation in the case. Federal had prosecutors accused Todd Clawson, who left the company in 2012, of participating in a scheme to bribe VA physicians to use the DermaGraft diabetic […]
Rani Therapeutics nabs $53m for robotic pill injection tech
Rani Therapeutics has raised $53 million to support manufacturing as it gears up for clinical trials of its robotic pill technology. New investors like GeneScience Pharmaceuticals and Shire (NSDQ:SHPG) joined existing investors like Alphabet’s GV, Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN). Rani Therapeutics, an InCube Lab spin-out started in 2012, has developed a capsule that delivers an intestinal injection […]
How this biotech plans to go up against big pharma with its eye disease products
Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s […]
Shire taps Rani Therapeutics’ oral delivery tech for hemophilia therapy
Shire (NSDQ:SHPG) said this week that it is collaborating with Rani Therapeutics to combine the company’s Rani Pill technology for the delivery of factor VIII therapy in patients with hemophilia A. According to the terms of the deal, Shire has the exclusive option to negotiate a license to develop and commercialize the technology as a delivery […]
BioDelivery Sciences president, CEO Sirgo to retire | Personnel Moves – Aug 29, 2017
BioDelivery Sciences (NSDQ:BDSI) said last week that its president & CEO, Mark Sirgo, plans to retire at the end of this year. Sirgo has held the corner office at the Raleigh, N.C.-based company since 2005. He will stay on as vice chairman of the board and will help determine his successor, BioDelivery Sciences reported. “After thirteen […]
Another extended-release ADHD drug wins FDA nod
Days after Neos Therapeutics (NSDQ:NEOS) nabbed U.S. regulatory approval for its controlled-release formulation of methylphenidate, Shire (NSDQ:SHPG) said it won a nod from the FDA for its long-acting ADHD drug. The drug, Mydayis, is made up of the same active ingredient in Shire’s ADHD treatment Adderall XR – amphetamine – but it is designed to last up to […]
